Clinical trial

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

NCT06043973

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention almonertinib Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-09-01

PhasePHASE3

Conditions

Advanced Non-small Cell Lung Cancerunresolved

Interventions

almonertinibDRUG

Sponsors & collaborators

Qianfoshan Hospitallead sponsor

Mapped research locations

JinanShandong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06043973 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.